Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease characterized by recurrent itchy, dry, and inflamed skin lesions, often beginning in childhood and persisting or recurring in adults.
A mouse study identified **TRPV4** as part of the neural feedback system that tells the brain when scratching has been sufficient. The findings suggest broadly blocking TRPV4 may not be the solution for chronic itch.
Animal health markets are projected to expand in 2026, led by animal biotechnology at $34.6 billion to $36.19 billion and continued growth in veterinary antibiotics. Demand is being driven by companion animal care, livestock health, biologics R&D, and tighter oversight of antibiotic use.
Arcutis is in focus after new Phase 3 extension data for Zoryve cream 0.05% in young children with atopic dermatitis and ahead of its Feb. 25 Q4 results. Investors are also watching recent FDA actions and pipeline updates for additional pediatric and dermatology indications.
Aurobindo Pharma's subsidiaries secured Health Canada approval for bevacizumab biosimilar Bevqolva, an EU distribution deal with STADA for two EMA-approved biosimilars, and US FDA approval for ADQUEY ointment for atopic dermatitis.
Aclaris Therapeutics outlined its TSLP antibody and ITK kinase pipeline at the Guggenheim Biotech Summit, with Phase II AD results for bosakitug due in late 2026 and Phase 1b studies for bispecific ATI-052 underway. The company will also announce Phase 1a results for ATI-052 and lead indication selection for ATI-2138 on April 28, 2026.
Merck is expanding its AI efforts through partnerships with Google Cloud and Mayo Clinic. The company said it will deploy AI across R&D and use multimodal clinical datasets to support drug discovery and precision medicine.
MSD signed a Google Cloud agreement worth up to $1 billion and entered an AI-focused R&D collaboration with Mayo Clinic. The deals expand AI use in drug discovery, development and broader operations.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.
Nektar said extended rezpeg treatment promoted greater hair growth in severe alopecia areata and reported durable 52-week efficacy for rezpegaldesleukin in atopic dermatitis. The company said it has FDA alignment on Phase 3 design and is targeting a BLA submission by 2029.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07599878 |
Adjunctive Group Psychotherapy for Moderate-to-Severe Atopic Dermatitis: A Pilot Feasibility Study Comparing Two Interventions |
COMPLETED | NA |
| NCT07599813 |
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis |
RECRUITING | PHASE2 |
| NCT07598383 |
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07592585 |
Phase III Clinical Study of VC005 in Adult and Adolescents With Mild to Moderate Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE3 |
| NCT07577921 |
Evaluation of the Efficacy of a Cosmetic Care in Subjects With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments |
COMPLETED | |
| NCT07574242 |
Effect of vitk2 on Atopic Dermatitis Pediatrics Patients |
COMPLETED | NA |
| NCT07560618 |
Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream. |
NOT_YET_RECRUITING | PHASE4 |
| NCT07559773 |
The ROOT Study: Scaling the 'Standard of Care Plus' Obstetric Nutrition Model to Optimize Maternal and Infant Health |
NOT_YET_RECRUITING | NA |
| NCT07549984 |
A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07549828 |
Sebum Metabolomics and Lipidomics for Clinical Applications |
NOT_YET_RECRUITING | NA |
